Josef Parvizi Sells 16,714 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 16,714 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $20.27, for a total transaction of $338,792.78. Following the completion of the transaction, the director directly owned 722,652 shares in the company, valued at $14,648,156.04. The trade was a 2.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Josef Parvizi also recently made the following trade(s):

• On Thursday, January 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $22.94, for a total transaction of $573,500.00.
• On Monday, December 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $21.49, for a total value of $537,250.00.
• On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $20.26, for a total value of $506,500.00.

CeriBell Stock Performance

Shares of CeriBell stock traded down $0.33 during trading on Monday, reaching $19.89. The company’s stock had a trading volume of 148,185 shares, compared to its average volume of 338,256. The business’s 50-day moving average price is $21.34 and its 200-day moving average price is $16.07. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $26.04. The firm has a market cap of $737.92 million, a PE ratio of -13.17 and a beta of 1.03. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12.

Institutional Trading of CeriBell

Several institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. raised its position in shares of CeriBell by 41.4% in the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after acquiring an additional 854 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares during the period. Deutsche Bank AG raised its stake in CeriBell by 1.7% during the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock worth $1,868,000 after buying an additional 1,393 shares during the period. Finally, Royal Bank of Canada lifted its holdings in shares of CeriBell by 10.8% in the 4th quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock worth $342,000 after purchasing an additional 1,514 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Canaccord Genuity Group increased their price objective on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. TD Cowen restated a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. JPMorgan Chase & Co. reduced their price objective on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Finally, BTIG Research reissued a “buy” rating and set a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, CeriBell currently has an average rating of “Moderate Buy” and an average price target of $24.67.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.